Press Releases
Company News
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Nov 7, 2012
PDF 9.2 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2012 Financial Results Teleconference on November 9, 2012
Nov 2, 2012
PDF 9.5 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Data From XTANDI(R) (enzalutamide) Pivotal Study
Sep 30, 2012
PDF 64.5 KB Add to Briefcase
View Summary Medivation Effects a 2-For-1 Forward Split of Its Common Stock
Sep 24, 2012
PDF 9.2 KB Add to Briefcase
View Summary Medivation and Astellas Announce XTANDI(R) (Enzalutamide) Is Now Available for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Sep 13, 2012
PDF 63.0 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Sep 4, 2012
PDF 9.2 KB Add to Briefcase
View Summary U.S. FDA Approves XTANDI(R) (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Aug 31, 2012
PDF 65.5 KB Add to Briefcase
View Summary Medivation Announces a 2-for-1 Forward Split of Its Common Stock
Aug 28, 2012
PDF 9.4 KB Add to Briefcase
View Summary New England Journal of Medicine Publishes Results From Phase 3 AFFIRM Trial of Enzalutamide
Aug 15, 2012
PDF 12.0 KB Add to Briefcase
View Summary Medivation Reports Second Quarter Financial Results and Provides Corporate Update
Aug 9, 2012
PDF 23.1 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Aug 8, 2012
PDF 8.8 KB Add to Briefcase
View Summary Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA
Aug 3, 2012
PDF 9.3 KB Add to Briefcase
View Summary Medivation Announces Second Quarter 2012 Financial Results Teleconference on August 9, 2012
Aug 2, 2012
PDF 7.3 KB Add to Briefcase
View Summary Enzalutamide Granted Priority Review by U.S. FDA for the Potential Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
Jul 24, 2012
PDF 11.1 KB Add to Briefcase
View Summary Astellas and Medivation Announce European Regulatory Submission for Enzalutamide for the Treatment of Men With Advanced Prostate Cancer Post-Chemotherapy
Jun 26, 2012
PDF 11.4 KB Add to Briefcase
View Summary Medivation and Astellas Provide Update on PREVAIL Enrollment
Jun 6, 2012
PDF 12.4 KB Add to Briefcase
View Summary Medivation and Astellas Announce Enzalutamide Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event
Jun 2, 2012
PDF 12.5 KB Add to Briefcase
View Summary Medivation and Astellas Announce Initiation of Expanded Access Program for Enzalutamide (formerly MDV3100) in the United States
May 30, 2012
PDF 12.6 KB Add to Briefcase
View Summary Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
May 21, 2012
PDF 11.8 KB Add to Briefcase
View Summary Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012
May 18, 2012
PDF 10.9 KB Add to Briefcase
Showing 61-80 of 303 Page: 1 2 3 4 5 6 7 8 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top